Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -101.42 Million EUR | 29.21% |
| 2022 | -143.27 Million EUR | -95.14% |
| 2021 | -73.42 Million EUR | -14.03% |
| 2020 | -64.39 Million EUR | -3592.26% |
| 2019 | -1.74 Million EUR | -153.43% |
| 2018 | 3.26 Million EUR | 128.43% |
| 2017 | -11.48 Million EUR | 76.66% |
| 2016 | -49.18 Million EUR | -138.56% |
| 2015 | -20.61 Million EUR | 21.52% |
| 2014 | -26.27 Million EUR | -8.97% |
| 2013 | -24.11 Million EUR | -62.46% |
| 2012 | -14.84 Million EUR | -235.85% |
| 2011 | -4.41 Million EUR | 44.5% |
| 2010 | -7.96 Million EUR | -29.59% |
| 2009 | -6.14 Million EUR | -157.18% |
| 2008 | -2.38 Million EUR | 28.94% |
| 2007 | -3.36 Million EUR | -1283.54% |
| 2006 | -243 Thousand EUR | 80.08% |
| 2005 | -1.22 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -24.93 Million EUR | -142.32% |
| 2024 Q1 | 58.9 Million EUR | 283.19% |
| 2023 Q4 | -32.15 Million EUR | 6.04% |
| 2023 Q2 | -16.91 Million EUR | 6.66% |
| 2023 Q3 | -34.22 Million EUR | -102.29% |
| 2023 FY | -101.42 Million EUR | 29.21% |
| 2023 Q1 | -18.12 Million EUR | 58.99% |
| 2022 Q2 | -145.45 Million EUR | -458.55% |
| 2022 Q1 | -26.04 Million EUR | -115.1% |
| 2022 FY | -143.27 Million EUR | -95.14% |
| 2022 Q4 | -44.2 Million EUR | -161.04% |
| 2022 Q3 | 72.41 Million EUR | 149.79% |
| 2021 Q1 | -27.7 Million EUR | -1245.41% |
| 2021 Q2 | -58.69 Million EUR | -111.89% |
| 2021 FY | -73.42 Million EUR | -14.03% |
| 2021 Q4 | 172.5 Million EUR | 208.13% |
| 2021 Q3 | -159.53 Million EUR | -171.79% |
| 2020 Q2 | -24.41 Million EUR | -1886.17% |
| 2020 Q4 | -2.05 Million EUR | 94.39% |
| 2020 FY | -64.39 Million EUR | -3592.26% |
| 2020 Q1 | -1.22 Million EUR | -278.12% |
| 2020 Q3 | -36.69 Million EUR | -50.33% |
| 2019 Q2 | -7.25 Million EUR | -249.47% |
| 2019 Q4 | 690 Thousand EUR | 2190.91% |
| 2019 FY | -1.74 Million EUR | -153.43% |
| 2019 Q1 | 4.85 Million EUR | -25.53% |
| 2019 Q3 | -33 Thousand EUR | 99.55% |
| 2018 Q1 | 1.45 Million EUR | 139.64% |
| 2018 FY | 3.26 Million EUR | 128.43% |
| 2018 Q4 | 6.51 Million EUR | 312.97% |
| 2018 Q3 | -3.06 Million EUR | -85.23% |
| 2018 Q2 | -1.65 Million EUR | -213.31% |
| 2017 FY | -11.48 Million EUR | 76.66% |
| 2017 Q4 | -3.67 Million EUR | -6.86% |
| 2017 Q2 | -2.7 Million EUR | -63.25% |
| 2017 Q3 | -3.44 Million EUR | -27.25% |
| 2017 Q1 | -1.65 Million EUR | 39.01% |
| 2016 Q1 | -5.03 Million EUR | -546.6% |
| 2016 FY | -49.18 Million EUR | -138.56% |
| 2016 Q4 | -2.71 Million EUR | 61.22% |
| 2016 Q3 | -7 Million EUR | 79.64% |
| 2016 Q2 | -34.42 Million EUR | -583.38% |
| 2015 Q2 | -8.97 Million EUR | -78.72% |
| 2015 Q1 | -5.01 Million EUR | 56.43% |
| 2015 FY | -20.61 Million EUR | 21.52% |
| 2015 Q4 | -779 Thousand EUR | 86.68% |
| 2015 Q3 | -5.85 Million EUR | 34.78% |
| 2014 Q4 | -11.52 Million EUR | -348.6% |
| 2014 Q3 | -2.56 Million EUR | 49.36% |
| 2014 Q1 | -7.11 Million EUR | -17.98% |
| 2014 FY | -26.27 Million EUR | -8.97% |
| 2014 Q2 | -5.07 Million EUR | 28.7% |
| 2013 Q2 | -5.56 Million EUR | -118.32% |
| 2013 Q3 | -9.96 Million EUR | -79.12% |
| 2013 Q1 | -2.54 Million EUR | 48.09% |
| 2013 FY | -24.11 Million EUR | -62.46% |
| 2013 Q4 | -6.02 Million EUR | 39.53% |
| 2012 Q4 | -4.91 Million EUR | -102.22% |
| 2012 Q3 | -2.42 Million EUR | 0.0% |
| 2012 FY | -14.84 Million EUR | -235.85% |
| 2011 FY | -4.41 Million EUR | 44.5% |
| 2010 FY | -7.96 Million EUR | -29.59% |
| 2009 FY | -6.14 Million EUR | -157.18% |
| 2008 FY | -2.38 Million EUR | 28.94% |
| 2007 FY | -3.36 Million EUR | -1283.54% |
| 2006 FY | -243 Thousand EUR | 80.08% |
| 2005 FY | -1.22 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -35.305% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1442.386% |
| SQZ Biotechnologies Company | -79.46 Million USD | -27.641% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 291.451% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 255.726% |
| Mesoblast Limited | -87.95 Million USD | -15.318% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -5471.406% |
| Genus plc | 7.9 Million USD | 1383.911% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -831.247% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2633.763% |
| Marizyme, Inc. | -65.34 Million USD | -55.216% |
| ContraFect Corporation | -65.15 Million USD | -55.678% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -1046.868% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1975.884% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5771.586% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -3406.749% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1158.474% |
| MultiCell Technologies, Inc. | -380.07 USD | -26686826.093% |
| Accustem Sciences Inc. | -3.74 Million USD | -2607.359% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -96.218% |
| EV Biologics, Inc. | -1.26 Million USD | -7904.599% |
| Q BioMed Inc. | -2.05 Million USD | -4842.71% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2617.091% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -15938.564% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -4160.165% |
| Biomind Labs Inc. | -1.21 Million USD | -8252.748% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -861.595% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1183.409% |
| Skye Bioscience, Inc. | -37.64 Million USD | -169.437% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -4574.548% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -677176.976% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1352.547% |
| IMV Inc. | -36.48 Million USD | -177.997% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -539.066% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1643.589% |
| GB Sciences, Inc. | -1.36 Million USD | -7348.83% |
| Alpha Cognition Inc. | -13.77 Million USD | -636.457% |
| HST Global, Inc. | -146.21 Thousand USD | -69272.136% |
| CSL Limited | 2.64 Billion USD | 103.839% |
| Halberd Corporation | -79.67 Thousand USD | -127201.822% |
| Enzolytics Inc. | -2.17 Million USD | -4559.478% |
| Resverlogix Corp. | -3.61 Million USD | -2709.668% |
| Affymax, Inc. | -14.42 Million USD | -603.196% |
| SYBLEU INC | -180.3 Thousand USD | -56154.437% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -3098.204% |
| argenx SE | -295.05 Million USD | 65.623% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -62.03% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 103598.98% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2452.962% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -3251.767% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1481.456% |
| Zenith Capital Corp. | -10.59 Million USD | -857.239% |
| Genscript Biotech Corporation | -95.47 Million USD | -6.234% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -436303.924% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2346.468% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -167715.977% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -69.826% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -3170.038% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -9504.501% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -5103.491% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2555.905% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4958.513% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1095.676% |
| ONE Bio Corp. | 8.67 Million USD | 1268.993% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -22880.545% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7495.226% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -5680.184% |
| Agentix Corp. | -1.37 Million USD | -7280.89% |
| LadRx Corporation | 400.44 Thousand USD | 25429.198% |
| Cell Source, Inc. | -5.32 Million USD | -1806.126% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -24312.546% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10009.937% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10009.937% |
| NovAccess Global Inc. | -4.76 Million USD | -2026.757% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1564.765% |
| Itoco Inc. | -1.86 Million USD | -5326.927% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -2183.133% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -5977.232% |
| Kadimastem Ltd | -3.3 Million USD | -2966.731% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -36998.851% |
| CytoDyn Inc. | -49.84 Million USD | -103.505% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -128237.53% |
| Mobile Lads Corp. | -2.26 Million USD | -4381.481% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -44361.638% |
| Qrons Inc. | -789.34 Thousand USD | -12749.735% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -10672.796% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4758.451% |
| Rebus Holdings, Inc. | -1.02 Million USD | -9844.02% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -6189.246% |
| International Stem Cell Corporation | -131 Thousand USD | -77326.718% |
| Bioxytran, Inc. | -4.28 Million USD | -2269.835% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -186790.109% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -3908.66% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -110.994% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4697.966% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -12888.947% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -3101.673% |
| Neutra Corp. | -233.46 Thousand USD | -43345.056% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -399.872% |
| PureTech Health plc | -65.69 Million USD | -54.389% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -376.942% |
| IXICO plc | -1.17 Million USD | -8510.272% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -921.749% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -77.547% |
| CSL Limited | 2.64 Billion USD | 103.839% |
| Cellectis S.A. | -103.17 Million USD | 1.691% |